Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surge
It marks J&J's first quarterly results since the company completed the separation from its consumer health spinoff Kenvue in August.
Read More
Johnson & Johnson
Earnings playbook: Netflix and Goldman Sachs headline a big week of reports
Expectations for the overall earnings season are muted. Source link
Read More
Regional banks are in focus in the week ahead as third-quarter earnings season ramps up
Regional bank earnings are expected to be a weak point this earnings season. Source link
Read More
Federal judge declines to block Medicare drug price negotiations
Judge Michael Newman of the Southern District of Ohio issued a ruling denying a preliminary injunction sought by the Chamber of
Read More
AstraZeneca, Bristol Myers Squibb to participate in Medicare drug price negotiations
AstraZeneca, Bristol Myers Squibb and other drugmakers have filed at least eight lawsuits seeking to declare the Medicare price talks
Read More
Johnson & Johnson is getting rid of its script logo after more than 130 years
The health care giant said Thursday that it will replace the well-known signature script it has used since 1887 with
Read More
These 10 medications are likely targets for Medicare price negotiations this fall
It's still unclear which drugs Medicare will select, but several companies have revealed in court filings that four of their
Read More
X CEO Linda Yaccarino explains reason for getting rid of Twitter name
X CEO Linda Yaccarino explained to CNBC on Thursday why the company decided to get rid of its Twitter branding.
Read More
Kenvue CEO says consumers are spending on brand-name health products even as they pull back in other areas
Thibaut Mongon's remarks follow Kenvue's second-quarter earnings beat, which was fueled by resilient demand for brands like Band-Aid, Tylenol and
Read More